Despite the jurisdictional posturing in Maryland, Virginia and Washington D.C. over a possible Amazon headquarters, a new FBI building or a national football stadium, the recent joint trade mission to Canada by their respective leaders — along with efforts such as the Greater Washington Board of Trade holding its summit at the Pendry Hotel in Baltimore — all augur well for better regional cooperation.
BioMarker Strategies, LLC today announced that the National Cancer Institute (NCI) has awarded the Company a Phase I Small Business Innovation Research (SBIR) grant for development of a pathway-based companion diagnostic test to identify patients with head and neck squamous cell carcinoma (HNSCC) who are most likely to respond to treatment with cetuximab. The grant will provide $299,000 in research support.
WellDoc®, a leading digital health company, announced today the appointment of Laurel Pickering, president and CEO of Northeast Business Group on Health (NEBGH), as the Company’s new Chief Revenue Officer (CRO). Ms. Pickering selected WellDoc as her next opportunity after spending nearly 25 years at the helm of NEBGH, an employer-led coalition of healthcare leaders and other stakeholders. Ms. Pickering will join the WellDoc team in October.
Three prominent Chinese executives discuss the progress of local companies in drug innovation and the evolving regulatory environment.
Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has completed its acquisition of raxibacumab, a fully human monoclonal antibody approved by the U.S. Food and Drug Administration (FDA) for the treatment and prophylaxis of inhalational anthrax, from GSK (LSE:GSK) (NYSE:GSK). With the acquisition, Emergent also plans to assume responsibility for a multi-year contract with the Biomedical Advanced Research and Development Authority (BARDA), valued at up to approximately $130 million to supply the product to the U.S. Strategic National Stockpile (SNS) through November 2019. The completion of the acquisition follows the satisfaction or waiver by the parties, as applicable, of all closing conditions, including expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act), as amended.
Effective September 26, 2017, the Board of Directors (the “Board”) of Sorrento Therapeutics, Inc. (Nasdaq: SRNE) appointed each of Dorman Followwill and David Lemus as an independent director of the Company.
The MIDC and ScienceAbroad, the organization of Israeli scientists abroad, jointly present a revealing program on the bio-tech entrepreneurial ecosystem of Israel and how it created “The Startup Nation,” featuring prominent Israeli scientific and entrepreneurial leaders.
Wednesday, Nov. 1st 5:30-7:30 p.m., Hosted by LifeBridge Health, Baltimore, MD
Thursday, Nov. 2nd 5:30-7:30 p.m., Suburban Hospital, Bethesda, MD
When: October 25, 2017 7:30 AM – 12 PM
Where: MITRE 7525 Colshire Drive McLean, VA 22102 United States
The Technology Showcase emphasizes the National Capital area’s culture of technology innovation and leadership. The conference also highlights Washington’s unique competitive advantage for commercial technology companies: access to policy-makers, government technology buyers, and national security services.
Health Canada has approved the probiotic Visbiome as a Natural Health Product for treating symptoms of irritable bowel syndrome in adults and children aged older than 5 years, the manufacturer announced.
Emergent BioSolutions Inc. (EBS) today announced that it has completed a new five-year, $200 million syndicated senior secured credit facility. This new facility replaces and represents an increase from the Company’s prior $100 million facility, which was scheduled to expire in December 2018. The new facility enhances the Company’s financial flexibility, providing increased capacity to drive growth through strategic acquisitions along with working capital as needed.
